Reviewer's report

Title: N-terminal pro-brain natriuretic peptide levels in patients with anomalous left coronary artery from pulmonary artery

Version: 0 Date: 18 Nov 2019

Reviewer: Shaoyi Zheng

Reviewer's report:

ALCAPA is a rare congenital heart disease which is associated with adult sudden death and early infant mortality. The most effective treatment is surgical coronary artery rebuilding and the result is perfect. However, few serum indexes were used to indicates the severity of ALCAPA. NT-pro-BNP has also been indicated as a strong independent prognostic factor in patients with various CHD. The authors tried to show the relationship between NT-pro-BNP and LVEF, Mitral regurgitation (grade). Finally, in patients with ALCAPA, NT-pro-BNP levels showed a negative correlation with age and LVEF when NT-pro-BNP above 300 pg/mL and no correlation with age and LVEF when NT-pro-BNP under 300 pg/ml. The article is interesting. However there are some concerns regarding the case report.

1. The paper need a native English speaker to revise the manuscript.

2. Heart failure is not the KEY WORD.

3. Patient presenting early will be expected to have increased BNP and in late presention the BNP could be normal. What is the clinical question or hypothesis is this study trying to answer?

4. Details about the study design, duration need to be provided. Details about the statistical methods used have not been provided.

5. Why you selected 300 as NT-pro-BNP cutoff value?

Level of interest
Please indicate how interesting you found the manuscript:

An article whose findings are important to those with closely related research interests

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests'

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal